PharmaLive talked to Gerald Martinetz at Mindbreeze regarding how data is transforming R&D in the metaverse.

Of all the communities touched by the COVID-19 pandemic, healthcare professionals (HCPs) are arguably among those most affected. Specialists on the front lines in primary care, critical care, infectious diseases, and pulmonology roles have experienced COVID-19 first hand—often risking their own health and that of their families to help. A new report from Apollo Intelligence provides a barometer on physicians’ sentiments for 2022, and together with other research, frames a wake-up call to medical device and pharma teams in charge of building a brand presence with prescribers.

Relevate Health solidified the healthcare marketing agency’s position as a market leader in healthcare professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems.

It’s no longer science fiction. The use of drones promises to provide those with chronic medical conditions with faster and easier access to the therapies they need.

More than 400 leaders within the pharmaceutical and biotech industries signed an open letter condemning the invasion of Ukraine and calling for “economic disengagement” from Russia.

A national survey by Press Ganey – the leader in healthcare consumer and employee experience – revealed heightened consumer expectations and information needs from pharma brands, presenting a unique opportunity for life sciences companies to drive brand strength.

Remember back in March and April and May of 2020, when people prefaced their plans for the future with, “When we get back to normal”? We never did, and we never will. The COVID experience has forever changed how all of us view the world, how we interact with each other … and, of course, how we interact with healthcare brands and what we expect from them. In seeking out insights from pharma’s wise heads for Med Ad News’ annual Agenda report, we tried to maneuver around COVID at least a little, to see what else was going on in the industry. But the plain fact is that we couldn’t, not really.

President Joe Biden called for the U.S. Senate to approve his Build Back Better legislation to reduce the costs of prescription drugs provided through Medicare and cap out-of-pocket drug costs for seniors.

Read Roberts, director of Key Opinion Leaders (KOL) data solutions at PRECISIONscientia, believes 2022 will see social media platforms as the new method for handling pharma medical education and peer-to-peer communications. So pharma must embrace a new type of digital sleuthing to find KOLs and Digital Opinion Leaders (DOLs), but they must do so carefully and think how to mitigate many risks in this highly regulated market, according to Roberts.

epocrates, an athenahealth Inc. company that delivers digital clinical decision support to prescribers, shared its commitment to accelerate the company’s fast-growing commercial business and further invest in and innovate its commercial product offerings, following a period of tremendous change in the pharmaceutical industry. To help enhance and broaden epocrates’ services, the company recently brought on Matt Titus – an industry veteran of 13 years – to serve as the organization’s vice president, chief commercial officer.